Mexitory

Atorvastatin, the active ingredient in Mexitory, is a HMG‑CoA reductase inhibitor presented as an oral tablet for systemic use. It lowers elevated cholesterol and triglyceride levels and is used to manage hypercholesterolemia, mixed dyslipidemia, and to reduce cardiovascular risk in appropriate patients.

GNH USA supplies Mexitory as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Atorvastatin, the generic name for Mexitory, acts on lipid metabolism to improve cholesterol profiles.

- Hypercholesterolemia: reduces low‑density lipoprotein (LDL) cholesterol and total cholesterol levels. - Mixed dyslipidemia: lowers triglycerides and raises high‑density lipoprotein (HDL) cholesterol. - Cardiovascular risk reduction: helps prevent myocardial infarction, stroke and other atherosclerotic events in patients at elevated risk.

Adverse reactions may occur with any medication and should be monitored.

Common Side Effects: - Muscle aches or weakness - Headache - Nausea or abdominal discomfort - Elevated liver enzymes - Diarrhea - Constipation

Serious or Rare Side Effects: - Rhabdomyolysis (severe muscle breakdown) - Acute liver injury - Severe allergic reactions (rash, angioedema) - Myopathy with marked CK elevation

Patients should be evaluated for safety before initiating therapy.

- Liver function monitoring: assess baseline transaminases and repeat periodically. - Muscle health: advise patients to report unexplained muscle pain, tenderness or weakness. - Drug interactions: review concomitant medications that may increase statin exposure. - Pregnancy and lactation: avoid use unless clearly indicated, as safety data are limited. - Renal impairment: adjust therapy based on renal function where appropriate. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Atorvastatin may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may markedly increase atorvastatin levels. - Gemfibrozil: significantly raises risk of myopathy. - Cyclosporine: enhances statin exposure and muscle toxicity.

Moderate Interactions (Monitor Closely): - Antacids (e.g., aluminum hydroxide): may modestly increase serum concentrations. - Warfarin: may potentiate anticoagulant effect, requiring INR monitoring. - Digoxin: slight increase in plasma levels may occur.